Skip to main content

RA Capital Management — Portfolio, Page 7

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
16
Industries
Biotechnology 19Medical 13Health Care 11Life Science 8Pharmaceutical 7Therapeutics 7+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 145168 of 453
ILiAD Biotechnologies
February 2026

ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.

Biotechnology · New York$115.0M Series D
Hemab
October 2025

Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.

Biotechnology · Copenhagen$157.0M Series C
VitriVax
October 2025

VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.

Biotechnology · Boulder$17.3M Series B
Adcytherix
October 2025

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

Biotechnology · Marseille$122.4M Series A
Indapta Therapeutics
October 2025

Indapta Therapeutics is a privately held biotechnology company.

Biopharma · San Francisco$50.8M Venture - Series Unknown
Ansa Biotechnologies
October 2025

Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.

Biotechnology · Emeryville$45.2M Series B
Star Therapeutics
September 2025

Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.

Health Care · South San Francisco$125.0M Series D
Sparrow Pharmaceuticals
September 2025

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.

Biopharma · Portland$95.0M Series B
Delix Therapeutics
September 2025

Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.

Biotechnology · Boston$25.0M Series B
Gameto
August 2025

Gameto is a biotechnology company developing therapeutics of the female reproductive system using cell engineering.

Biopharma · New York$44.0M Series C
Spyglass Pharma
June 2025

Spyglass Pharma provides medicine for ophthalmic diseases.

Delivery · Aliso Viejo$75.0M Series D
Imbria Pharmaceuticals
April 2025

Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.

Biotechnology · Boston$59.2M Series B
Vaxess Technologies
April 2025

Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.

Biotechnology · Cambridge$9.0M Venture - Series Unknown
Vivace Therapeutics
March 2025

Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.

Biotechnology · San Mateo$35.0M Series D
Bambusa Therapeutics
February 2025

Bambusa Therapeutics operates as biotechnology company.

Biotechnology · Boston$90.0M Series A
AmbAgon Therapeutics
February 2025

AmbAgon Therapeutics is a developer of cancer molecule therapeutics.

Biotechnology · San Francisco$5.0M Venture - Series Unknown
Synapticure
November 2024

We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US

Health Care · Chicago$25.0M Series A
Trace Neuroscience
November 2024

Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients.

Biotechnology · South San Francisco$101.0M Series A
INNOVENTRIC
October 2024

Innoventric, a start-up company from Ness-Ziona, Israel, develops the unique Trillium technology

Clinical Trials · Ness Ziona$28.5M Series B
Convergent Therapeutics
September 2024

Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.

Health Care · Cambridge$40.0M Series A
Superluminal Medicines
September 2024

Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.

Biotechnology · Boston$120.0M Series A
Elektrofi
August 2024

Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.

Alternative Medicine · Boston$112.3M Series C
Halda Therapeutics
August 2024

Halda Therapeutics is a research-stage drug discovery company.

Biotechnology · New Haven$126.0M Series B
Idrx
August 2024

Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.

Biotechnology · Cambridge$120.0M Series B

Where RA Capital Management invests

Biotechnology19
Medical13
Health Care11
Life Science8
Pharmaceutical7
Therapeutics7

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Medical, Health Care, Life Science, Pharmaceutical. The firm invests across 16 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Hemab received $157.0M in a Series C round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include ILiAD Biotechnologies, Hemab, VitriVax, Adcytherix, Indapta Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →